APYX
Apyx Medical Corporation
APYX offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over APYX overall, supported by lower modeled downside and stronger modeled upside.
APYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
APYX's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
APYX PE Valuation
APYX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
APYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
APYX has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
APYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.18 |
| Q2 2026 | -$0.20 | +$0.26 |
| Q1 2026 | -$0.22 | +$0.34 |
| Q4 2025 | -$0.27 | +$0.41 |
| Q3 2025 | -$0.37 | +$0.46 |
| Q2 2025 | -$0.46 | +$0.36 |
| Q1 2025 | -$0.56 | +$0.10 |
| Q4 2024 | -$0.68 | -$0.14 |
APYX is still losing money, but far less than before: $0.19 per share over the past year, against $0.83 at its worst in late 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over APYX on earnings quality, reporting a profit while its opponent remains loss making.
APYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14M | +9% |
| Q2 2026 | $13.9M | +22% |
| Q1 2026 | $12.5M | +32% |
| Q4 2025 | $19.2M | +35% |
| Q3 2025 | $12.9M | +12% |
| Q2 2025 | $11.4M | -6.4% |
| Q1 2025 | $9.4M | -7.9% |
| Q4 2024 | $14.2M | -3% |
APYX's revenue has grown year over year for five quarters in a row: $14M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.1% | +2.4 points |
| Q2 2026 | -13% | +9.6 points |
| Q1 2026 | -7.3% | +25 points |
| Q4 2025 | 0.1% | +22 points |
| Q3 2025 | -6.5% | +25 points |
| Q2 2025 | -23% | +23 points |
| Q1 2025 | -32% | +32 points |
| Q4 2024 | -21% | +18 points |
APYX's operating margin was −4.1% last quarter, up 2.4 points from the same quarter a year ago, near the top of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over APYX on profitability, with a higher operating margin.
APYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.9M | +$2.2M |
| Q2 2026 | -$3.6M | -$2.1M |
| Q1 2026 | -$632K | +$125K |
| Q4 2025 | -$2.8M | +$377K |
| Q3 2025 | -$4.1M | +$538K |
| Q2 2025 | -$1.5M | +$3.1M |
| Q1 2025 | -$757K | +$5.6M |
| Q4 2024 | -$3.2M | -$877K |
APYX has burned cash in almost every quarter: −$9M over the past year, against −$9M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over APYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
APYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +195K shares |
| 1 year | +8.1% | +3.3M shares |
| 3 years | +27% | +9.4M shares |
| 5 years | +28% | +9.7M shares |
| Available history | +29% | +10M shares |
APYX has 44M diluted shares, up 8.1% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over APYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
APYX Net Leverage
APYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
APYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 28.7 | Neutral |
APYX's weekly RSI is 44 (neutral) and its Stochastic is 29 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
APYX PE vs Healthcare Sector
APYX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
APYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 7.8% above |
| 20 week MA | $3.24 | 11% below |
| 50 week MA | $3.58 | 19% below |
| 100 week MA | $2.77 | 4.3% above |
| 200 week MA | $2.73 | 5.9% above |
APYX's trend is mixed: it's above three of its five weekly moving averages, and 5.9% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over APYX on trend strength, trading above more of its moving averages.
APYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.23 | $7.04 | -14% |
| 2021 | $7.04 | $13.1 | +86% |
| 2022 | $13.1 | $1.99 | -85% |
| 2023 | $1.99 | $2.62 | +32% |
| 2024 | $2.62 | $1.64 | -37% |
| 2025 | $1.64 | $3.44 | +110% |
| 2026 YTD | $3.44 | $2.89 | -16% |
APYX's yearly returns have swung widely, from +110% in 2025 to −85% in 2022. It's down 16% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over APYX on returns for 2026, with the stronger performance.